Table 5 Cost-effectiveness analyses of infant outcomes in the short-term
Option B | Option B+ | |
|---|---|---|
Cost | ||
Program Cost (Total 18 months) | US$1,229,338.47 | US$1,176,128.63 |
Pediatric outcomes | ||
Expected number of infection averted | 1016.85 | 1016.85 |
QALY averted | 58,801.02 | 58,801.02 |
Cost-effectiveness ratios | ||
Cost per infection averted | US$1208.96 | US$1156.63 |
Cost per QALY acquired | US$20.91 | US$20.00 |
Cost minimization in infection averted (compared to Option B) | – | Option B+ |
Cost minimization in QALY acquired(compared to Option B) | – | Option B+ |